ClinicalTrials.gg
CompletedNCT07608016RESMRESG101Updated Nov 18, 2026

A Study to Evaluate a Supplement Combination in Supporting Weight Loss, Metabolic Health, and Quality of Life

An interventional study of Combination Prebiotic and Postbiotic in Weight Loss, Metabolic Health and Quality of Life, sponsored by Able Biolabs, LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Able Biolabs, LLC · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jan 2026, registered Apr 2026).
Updated Nov 18, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,000 studies in Weight Loss with a site in United States — 119 open to participants now, 174 under way, 9 of them phase 3. Weight Loss · United States.

Enrollment
776th of 917
20 · median 72
Started
2026
with 49 others
No phase
714 of 1,000
72 open now
Registered
977th of 1,000
by date

Among the 1,000 studies in Weight Loss with a site in United States, this one is the 776th largest by enrollment of the 917 interventional ones that give a count, is one of 50 that started in 2026, is one of 714 with no phase, and was the 977th registered.

Weight Loss

1,821 studies on the registry are indexed under Weight Loss; 299 are open to participants now.

Browse Weight Loss studies →

Open to participants now

119 of the 1,000 studies in Weight Loss with a site in United States are open now. Recruiting first, the newest first:

114 more — sign in →

All 119 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 200 Weight Loss studies recruiting now, 74 (37%) set no upper age limit and 109 (55%) stop at 75 or younger; 21 take children under 18; 57 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,000 studies in Weight Loss with a site in United States, or all of them as a file.
02

Study summary

This consumer-use study evaluates the effects of a combined postbiotic and prebiotic supplement regimen on appetite control, cravings, metabolic health, energy, and quality of life in adults aged 18-65 years with a body mass index (BMI) between 25 and 30.

Participants will consume one capsule of resM™ GLP-1 Postbiotic and one scoop of resG prebeet ENERGY Prebiotic daily for 60 days. Data will be collected through daily check-ins, weekly surveys, and quality-of-life questionnaires administered through the Chloe mobile application.

The primary objective is to evaluate changes in appetite control and food cravings over 60 days of supplementation.

Read the detailed description

The GLP-1 Optimizer Bundle combines resM™ GLP-1 Postbiotic and resG prebeet ENERGY Prebiotic to support appetite control, cravings, metabolic health, energy, and lifestyle behaviors.

This is a prospective, open-label, single-arm consumer-use study conducted over 60 days in approximately 20 adults aged 18-65 years with BMI between 25 and 30.

Participants will consume:

one capsule of resM™ GLP-1 Postbiotic daily one scoop of resG prebeet ENERGY Prebiotic daily

Assessments will be collected electronically through the Chloe mobile application and include:

appetite and cravings surveys energy and mood assessments quality-of-life questionnaires lifestyle habit surveys consumer satisfaction assessments

The study aims to evaluate consumer-reported changes associated with daily supplementation and lifestyle guidance.

03

Conditions studied

  • Weight Loss
  • Metabolic Health
  • Quality of Life

Browse trials for

Keywords

  • weight loss
  • quality of life
  • metabolic health
  • supplement
  • prebiotic
  • postbiotic
  • energy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Adults aged 18-65 years between 25 and 30 Generally healthy Willing to comply with study procedures Access to smartphone or internet-enabled device for electronic questionnaires

Exclusion Criteria Pregnant, planning pregnancy, or lactating History of bariatric surgery Prescription weight loss medication use within the past 90 days Current GLP-1 drug use History of substance abuse within the past 6 months Current use of supplements containing overlapping active ingredients Significant medical condition that may interfere with study participation or interpretation of results

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Active Supplement Bundle

    resM™ GLP-1 Postbiotic, and resG prebeet ENERGY Prebiotic

    Dietary Supplement: Combination Prebiotic and Postbiotic

Interventions

  • Dietary supplementCombination Prebiotic and Postbiotic

    Participants will take a combined dosage of prebiotic and postbiotic.

06

What researchers measure

Primary outcomes

  1. Change in Appetite Control and Food Cravings Survey Scores Over 60 Days

    Participant-reported appetite control and food cravings will be assessed using daily and weekly questionnaires administered through the Chloe mobile application. Survey responses will evaluate changes in hunger, cravings, satiety, and eating behaviors over the study period.

    Time frame: Baseline through Day 60

Secondary outcomes

  1. Change in Quality-of-Life Questionnaire Responses Over 60 Days

    Quality-of-life assessments will evaluate participant-reported physical well-being, lifestyle habits, and overall satisfaction during the study period.

    Time frame: Baseline, Day 30, and Day 60

  2. Participant Satisfaction and Willingness to Recommend or Continue Product Use

    At the end of the study, participants reported overall satisfaction, whether they would recommend the product bundle, whether they would continue using it, and open-ended feedback about their experience. These responses were self-reported and descriptive.

    Time frame: End of Week 8

  3. Change in Participant-Reported Body Weight

    Participants reported body weight at baseline and weekly through Week 7. Percentage weight-loss thresholds, if included, are exploratory and descriptive.

    Time frame: Baseline and weekly through Week 7

  4. Adherence to Daily Supplement Use

    Participants completed daily forms reporting use of the study products. Adherence was summarized as the percentage of planned daily use reported during the 60-day study.

    Time frame: - Daily through Day 60

  5. Participants Reporting Adverse Events

    Adverse events were collected through daily forms. The outcome is the number of participants reporting an adverse event during the study, summarized by event and severity.

    Time frame: Daily through Day 60

07

Study locations

1 site
  • Able Biolabs, LLC
    Birmingham, Alabama 35203, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2026 to primary completion in May 2026, 3 months.

Of 671 non-industry interventional studies with no phase under Weight Loss, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's 3 months is below that.

Counting every sponsor, half of 730 studies reached it within 24 months; a quarter within 11 and three quarters within 43.

Start moved once since we started tracking on Sep 25, 2026: Oct 2025 → Jan 2026, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2026
First posted
May 27, 2026
StartActual
Jan 5, 2026was Oct 2025
Primary completionActual
May 1, 2026
CompletionActual
May 1, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 20, 2025→Jan 5, 2026
Nov 18, 2026
Primary completion
May 5, 2026→May 1, 2026
Nov 18, 2026
Study completion
May 5, 2026→May 1, 2026
Nov 18, 2026
Secondary outcomes
1 edited, 3 added, 1 removed
What changed in the outcomes
  • EditedParticipant Satisfaction and Willingness to Recommend or Continue Product Use at Day 60Time frame: Day 60 → End of Week 8
  • AddedChange in Participant-Reported Body WeightTime frame: Baseline and weekly through Week 7
  • AddedAdherence to Daily Supplement UseTime frame: - Daily through Day 60
  • AddedParticipants Reporting Adverse EventsTime frame: Daily through Day 60
  • RemovedChange in Energy and Mood Survey Scores Over 60 DaysTime frame: Baseline through Day 60
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Oct 20, 2025→Jan 5, 2026
    Primary completion May 5, 2026→May 1, 2026
    Study completion May 5, 2026→May 1, 2026
    Secondary outcomes 1 edited, 3 added, 1 removed
    What changed in the outcomes
    • EditedParticipant Satisfaction and Willingness to Recommend or Continue Product Use at Day 60Time frame: Day 60 → End of Week 8
    • AddedChange in Participant-Reported Body WeightTime frame: Baseline and weekly through Week 7
    • AddedAdherence to Daily Supplement UseTime frame: - Daily through Day 60
    • AddedParticipants Reporting Adverse EventsTime frame: Daily through Day 60
    • RemovedChange in Energy and Mood Survey Scores Over 60 DaysTime frame: Baseline through Day 60

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07608016
Lead sponsor
Able Biolabs, LLC
Responsible party
Sponsor
First posted
May 27, 2026
Start date
Jan 5, 2026
Primary completion
May 1, 2026
Completion
May 1, 2026
Last update
Nov 18, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion